Osteoporosis Therapeutics
1. Boniva patent expiration
Treatment: Treatment and prevention of osteoporosis; Treatment and prevention of osteoporosis
BONIVA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6143326 | HOFFMANN LA ROCHE | Oral pharmaceutical preparation containing ibandronat |
Apr, 2017
(8 years ago) | |
| US7718634 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 years ago) | |
| US6294196 | HOFFMANN LA ROCHE | Pharmaceutical composition containing diphosphonic acid or salt thereof |
Oct, 2019
(6 years ago) | |
| US7410957 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 years ago) | |
| US7192938 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 years ago) | |
Drugs and Companies using IBANDRONATE SODIUM ingredient
Market Authorisation Date: 16 May, 2003
Dosage: TABLET
How can I launch a generic of BONIVA before it's drug patent expiration?
More Information on Dosage
BONIVA family patents
2. Boniva patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5662918 | ROCHE | Pharmaceutical agents containing diphosphonic acids and salts thereof |
Sep, 2014
(11 years ago) | |
Drugs and Companies using IBANDRONATE SODIUM ingredient
Market Authorisation Date: 06 January, 2006
Dosage: INJECTABLE
How can I launch a generic of BONIVA before it's drug patent expiration?
More Information on Dosage
BONIVA family patents
3. Tymlos patent
expiration
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Use for detecting neutralizing antibodies; Treatment t...
TYMLOS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748382 | RADIUS | Method of drug delivery for bone anabolic protein |
Oct, 2027
(1 year, 8 months from now) | |
| US11680942 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog |
Jan, 2040
(14 years from now) | |
| US7803770 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(5 years from now) | |
| US11255842 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
Jan, 2040
(14 years from now) | |
| US11782041 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(12 years from now) | |
| USRE49444 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(5 years from now) | |
| US8148333 | RADIUS | Stable composition comprising a PTHrP analogue |
Nov, 2027
(1 year, 9 months from now) | |
| US11977067 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(12 years from now) | |
| US10996208 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| M(M-270) | Sep 20, 2024 |
| New Indication(I-907) | Dec 19, 2025 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Dosage: SOLUTION
How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage
TYMLOS family patents
4. Yorvipath patent expiration
Treatment: Treatment of hypoparathyroidism in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906847 | ASCENDIS PHARMA BONE | Prodrug comprising a drug linker conjugate |
Apr, 2031
(5 years from now) | |
| US11890326 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11918628 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12453778 | ASCENDIS PHARMA BONE | NA |
Sep, 2037
(11 years from now) | |
| US12403182 | ASCENDIS PHARMA BONE | NA |
Nov, 2042
(16 years from now) | |
| US12295989 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11857603 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(11 years from now) | |
| US11590207 | ASCENDIS PHARMA BONE | Dosage regimen for a controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11759504 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| New Chemical Entity Exclusivity(NCE) | Aug 09, 2029 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
Drugs and Companies using PALOPEGTERIPARATIDE ingredient
NCE-1 date: 09 August, 2028
Market Authorisation Date: 09 August, 2024
Dosage: SOLUTION
More Information on Dosage
YORVIPATH family patents
5. Zometa patent expiration
Treatment: Hypercalcemia of malignancy
ZOMETA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4939130 (Pediatric) | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar, 2013
(12 years ago) | |
| US4939130 | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep, 2012
(13 years ago) | |
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(7 months ago) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(2 years from now) | |
|
US8324189 (Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2011 |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Dosage: INJECTABLE
How can I launch a generic of ZOMETA before it's drug patent expiration?
More Information on Dosage
ZOMETA family patents